Arrowhead Pharmaceuticals (ARWR) Stock Looks Cheap On Cash Flow Yet Fair On Sales
Arrowhead Pharmaceuticals has delivered a very strong 197.0% 1 year return, yet the latest valuation checks point to a more nuanced picture, with the Discounted Cash Flow (DCF) intrinsic value estimate suggesting the stock trades at a large discount while market based multiples look closer to fair.
- The 197.0% return over the past year signals investors have quickly repriced Arrowhead Pharmaceuticals around its prospects.
- Fresh Phase 3 data for plozasiran in severe hypertriglyceridemia can support optimism about future cash flows, while the risk is that clinical, regulatory or commercial outcomes differ from current expectations.
- With a mixed overall value score, 3 out of 6 checks positive, Arrowhead Pharmaceuticals looks neither a clear bargain nor clearly expensive on the broader set of valuation measures.
The issue now is whether the current share price already reflects the intrinsic value suggested by the Discounted Cash Flow estimate or whether there is still a meaningful margin between price and value.
Scan other stocks that combine strong clinical news with valuation gaps by reviewing the hand picked 47 high quality undervalued stocks alongside Arrowhead Pharmaceuticals' latest move.
Does Arrowhead Pharmaceuticals Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) approach estimates what Arrowhead Pharmaceuticals could be worth based on projected future cash that flows to shareholders. For Arrowhead, the latest twelve month free cash flow is a loss of about $185 million, so the model assumes cash flows first recover from current losses and then grow, rather than staying at this level.
On that basis, the 2 Stage Free Cash Flow to Equity model points to an estimated intrinsic value of about $172 per share. Compared with the current share price, this implies the stock trades at a 49.9% discount and screens as undervalued on this method. Because the recent Phase 3 plozasiran data is already factored into expectations about future free cash flow, the remaining discount suggests the market is still cautious about how that pipeline translates into long term cash generation.
Overall, this DCF analysis indicates that Arrowhead Pharmaceuticals stock currently appears undervalued relative to its projected cash flows.
Our Discounted Cash Flow (DCF) analysis suggests Arrowhead Pharmaceuticals is undervalued by 49.9%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks.
Does Arrowhead Pharmaceuticals Look Fairly Valued on Sales?
P/S is a useful guide for Arrowhead Pharmaceuticals because revenue is a clearer anchor than earnings for a company that is still investing heavily and reporting losses.
Arrowhead Pharmaceuticals currently trades on a P/S of about 18.2x. This is above the broader Biotechs industry average of 13.2x, and also slightly above the peer group average of 17.3x. The valuation model that blends factors like growth expectations, profitability, size and risk points to a fair P/S ratio of about 17.9x for Arrowhead.
That fair ratio sits just below the current multiple, so the stock looks only marginally richer than what the model suggests as reasonable on sales. In other words, at today’s P/S, investors are paying a price that is broadly aligned with what the company’s revenue profile and risk level would imply.
Overall, Arrowhead Pharmaceuticals looks roughly fairly valued on the P/S multiple.
See what the numbers say about this price — find out in our valuation breakdown.
The Arrowhead Pharmaceuticals Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where this valuation puzzle for Arrowhead Pharmaceuticals leaves off. Narratives spell out which paths for Arrowhead Pharmaceuticals' growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price, and each one treats fair value as a thesis about the business that you can monitor over time rather than a single static number. They are available on Simply Wall St's Community page.
One of the top community narratives on Arrowhead Pharmaceuticals: 22% undervalued
"Multiple large pharma collaborations and milestone generating partnerships provide non dilutive capital, revenue diversity, and stability independent of volatile equity markets, supporting sustained R&D investments..."
Read one of the top narratives on Arrowhead Pharmaceuticals
Do you think there's more to the story for Arrowhead Pharmaceuticals? Head over to our Community to see what others are saying!
The Bottom Line
Arrowhead Pharmaceuticals screens as undervalued on a Discounted Cash Flow (DCF) view, while the P/S multiple suggests the stock is now priced roughly in line with peers. That split reflects a key question about how quickly current programs can translate into sustained, tangible cash flows. The broader, mixed valuation checks underline that this is not a straightforward mispricing but a debate about execution and timing. The crux from here is whether Arrowhead Pharmaceuticals can convert its pipeline into durable revenue that matches the intrinsic value estimate, or whether the present discount simply reflects the real clinical, regulatory and commercial risks ahead.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com